EUVIMEDEUVIMED entdecken
Crossref

Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillation

Stefan Peukert, Hatice Belgin Gulgeze Efthymiou, Ruowei Mo, Yunshan Peng, Fupeng Ma, Guillaume Barbe, Gregory Bebernitz, Cary Fridrich, Chiara Buono, Eric T Williams, Thomas Daniels, Lisha Li und 4 weitere

Bioorganic & Medicinal Chemistry Letters · 2023

DOI: 10.1016/j.bmcl.2023.129237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023. Verfasst von Stefan Peukert und 15 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Institutes for Biomedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: stefan.peukert@novartis.com. Hauptthemen laut MEDLINE: Atrial Fibrillation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and a significant risk factor for ischemic stroke and heart failure. Marketed anti-arrhythmic drugs can restore sinus rhythm, but with limited efficacy and significant toxicities, including potential to induce ventricular arrhythmia. Atrial-selective ion channel drugs are expected to restore and maintain sinus rhythm without risk of ventricular arrhythmia. One such atrial-selective channel target is GIRK1/4 (G-protein regulated inwardly rectifying potassium channel 1/4). Here we describe 14b, a potent GIRK1/4 inhibitor developed to cardiovert AF to sinus rhythm while minimizing central nervous system exposure - an issue with preceding GIRK1/4 clinical candidates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHumansElectric CountershockHeart AtriaBrain

Stichwörter der Autor:innen

Atrial fibrillationCardioversionGIRK1/4 inhibitorPeripherally restricted drug

Autor:innen und Institutionen

  • Novartis Institutes for Biomedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address: stefan.peukert@novartis.com.
  • Novartis Institutes for Biomedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Former Novartis Employee, USA.

Zitieren

APA

Peukert, S., Gulgeze Efthymiou, H. B., Mo, R., Peng, Y., Ma, F., Barbe, G., Bebernitz, G., Fridrich, C., Buono, C., Williams, E. T., Daniels, T., Li, L., Zhang, X., Adachi, Y., Abe, M., & Taggart, A. K. P. (2023). Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillation. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2023.129237

Vancouver

Peukert S, Gulgeze Efthymiou HB, Mo R, Peng Y, Ma F, Barbe G, et al. Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillation. Bioorganic & Medicinal Chemistry Letters. 2023. doi:10.1016/j.bmcl.2023.129237

BibTeX
@article{Peukert2023,
  author = {Peukert, Stefan and Gulgeze Efthymiou, Hatice Belgin and Mo, Ruowei and Peng, Yunshan and Ma, Fupeng and Barbe, Guillaume and Bebernitz, Gregory and Fridrich, Cary and Buono, Chiara and Williams, Eric T and Daniels, Thomas and Li, Lisha and Zhang, Xia and Adachi, Yuichiro and Abe, Mie and Taggart, Andrew K P},
  title = {Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillation},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2023},
  doi = {10.1016/j.bmcl.2023.129237}
}
Kostenlos starten →